Journal of autoimmunity最新文献_第3页

Pathophysiological effects of long COVID-19 (auto)antibodies on fertility COVID-19（自身）长抗体对生育能力的病理生理影响。

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2025-12-24 DOI: 10.1016/j.jaut.2025.103518

Laura Talamini , Cindy Verdot , Yehuda Shoenfeld , Sylviane Muller

引用次数: 0

Striatin-3 is a human autoantigen but it is not associated with the S-phase G2 nuclear antigen (SG2NA) staining pattern 纹状蛋白3是一种人类自身抗原，但它与s期G2核抗原（SG2NA）染色模式无关

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2025-11-25 DOI: 10.1016/j.jaut.2025.103503

Marvin J. Fritzler , Yoshinao Muro , Werner Klotz , Manfred Herold , Luis E.C. Andrade , Marcelle Grecco , Minoru Satoh , May Y. Choi , Maria Infantino , Edward K.L. Chan

{"title":"Striatin-3 is a human autoantigen but it is not associated with the S-phase G2 nuclear antigen (SG2NA) staining pattern","authors":"Marvin J. Fritzler , Yoshinao Muro , Werner Klotz , Manfred Herold , Luis E.C. Andrade , Marcelle Grecco , Minoru Satoh , May Y. Choi , Maria Infantino , Edward K.L. Chan","doi":"10.1016/j.jaut.2025.103503","DOIUrl":"10.1016/j.jaut.2025.103503","url":null,"abstract":"<div><div>Human autoantibodies have a long history of being valuable reagents to identify and characterize unique subcellular compartments, macromolecular complexes, and their individual components. One such discovery started as a unique cell-cycle related immunofluorescence pattern characterized as autoantibody targets localized in S and G2 phase nuclei of tissue culture cells, which became known as the “SG2NA” (SG2 nuclear antigen). These descriptions were followed by the identification of a calmodulin-binding protein family named ‘striatin’ that was later identified as three paralogs: Striatin/STRN1, Striatin-3/STRN3/SG2NA, and Striatin-4/STRN4/Zinedin. Many subsequent reports have used the designations SG2NA and striatin interchangeably. This report reviews the history of SG2NA and clarifies that striatin-3 is indeed a target autoantigen of some autoimmune sera, but commercially available striatin-3 antibodies or human sera that react with striatin-3 do not produce a SG2 phase nuclear staining pattern on HEp-2 cells. Hence, future reports should not use anti-SG2NA and anti-striatin interchangeably.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"158 ","pages":"Article 103503"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145584340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical work demands and risk of rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. A Danish longitudinal cohort study 体力劳动要求和类风湿关节炎、系统性硬化症和系统性红斑狼疮的风险。丹麦纵向队列研究

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2025-12-10 DOI: 10.1016/j.jaut.2025.103514

Helena Breth Nielsen , Nidhi Gupta , Astrid Juhl Andersen , Lene Wohlfahrt Dreyer , Esben Meulengracht Flachs , Ida E.H. Madsen , Henrik Albert Kolstad , Hans Kromhout , Camilla Sandal Sejbaek , Karin Sørig Hougaard

{"title":"Physical work demands and risk of rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. A Danish longitudinal cohort study","authors":"Helena Breth Nielsen , Nidhi Gupta , Astrid Juhl Andersen , Lene Wohlfahrt Dreyer , Esben Meulengracht Flachs , Ida E.H. Madsen , Henrik Albert Kolstad , Hans Kromhout , Camilla Sandal Sejbaek , Karin Sørig Hougaard","doi":"10.1016/j.jaut.2025.103514","DOIUrl":"10.1016/j.jaut.2025.103514","url":null,"abstract":"<div><h3>Objectives</h3><div>This study assesses the association between physical work demands and rheumatoid arthritis (RA), systemic sclerosis (SSc), and systemic lupus erythematosus (SLE) among men and women.</div></div><div><h3>Methods</h3><div>This nationwide, register-based study included more than 1.0 million women and 1.1 million men with employment born between 1960 and 1999 from the Danish Occupational Cohort with eXposure data (DOC∗X). Information on physical work demands was obtained from a job exposure matrix (JEM) and measured as recent physical work demands, accumulated physical work demands, and years with high physical work demands since workforce entry. The populations were followed from 1997 to 2018. Poisson regression models were used to estimate the IRRs for developing RA, SSc, and SLE, identified in the Danish National Patient Registry.</div></div><div><h3>Results</h3><div>Men in occupations with high recent physical work demands (4th quartile vs. 1st quartile: 1.36, 95 % CI 1.31–1.42), higher accumulated physical work demands, and more years with high physical work demands, had a higher risk of diagnosis of RA, while this was not the case for women. Accumulated physical work demands and more years with high physical work demands were associated with a small increased risk of diagnosis of SSc and SLE among men. In women, high physical work demands were associated with a reduced risk of diagnosis of SLE, while the results on SSc were inconsistent.</div></div><div><h3>Conclusion</h3><div>These findings support an association between higher physical work demands and diagnosis of RA and possibly, albeit to a lesser extent, SLE and SSc in men, but not in women.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"158 ","pages":"Article 103514"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145734026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study Daratumumab单药治疗逆转难治性狼疮性肾炎患者的免疫和促纤维化概况：一个试点案例研究

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2025-12-31 DOI: 10.1016/j.jaut.2025.103520

Dario Roccatello , Alice Barinotti , Massimo Radin , Irene Cecchi , Elena Rubini , Daniele Mancardi , Martina Cozzi , Roberta Fenoglio , Savino Sciascia

{"title":"Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study","authors":"Dario Roccatello , Alice Barinotti , Massimo Radin , Irene Cecchi , Elena Rubini , Daniele Mancardi , Martina Cozzi , Roberta Fenoglio , Savino Sciascia","doi":"10.1016/j.jaut.2025.103520","DOIUrl":"10.1016/j.jaut.2025.103520","url":null,"abstract":"<div><div>Refractory lupus nephritis (LN) poses a significant clinical challenge in the management of systemic lupus erythematosus (SLE) due to its resistance to conventional immunosuppressive therapies. This study evaluates the immunological, anti-inflammatory and anti-fibrotic effects of daratumumab, a CD38-targeting monoclonal antibody, in patients with refractory LN who failed standard treatments. Previous findings demonstrated daratumumab safety and efficacy, improving renal function and reducing proteinuria, anti-dsDNA antibodies, and SLEDAI-2K. In the present study, daratumumab treatment resulted in immunophenotypic remodelling, including increased CD3<sup>+</sup> and CD8<sup>+</sup> T-cell counts and decreased B-cell populations alongside significant reductions in fibrotic and inflammatory markers (APRIL, TNF-R1, TNF-R2, TWEAK, MMP-1, MMP-2, MMP-3). Additionally, a case study of a patient with antiphospholipid antibodies (aPL) and a history of recurrent thromboses and renal flares, demonstrated an improvement in thrombin generation and endothelial function. These results suggest daratumumab to be a promising and targeted therapeutic option for managing refractory LN by modulating immune and fibrotic responses.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"158 ","pages":"Article 103520"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145880513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prior murine neurotropic coronavirus infection ameliorates experimental autoimmune encephalitis 既往小鼠嗜神经性冠状病毒感染可改善实验性自身免疫性脑炎

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2025-11-24 DOI: 10.1016/j.jaut.2025.103504

Divyasha Saxena , Kelly Walter , Elizabeth Amona , Maiying Kong , Stanley Perlman , Jian Zheng

{"title":"Prior murine neurotropic coronavirus infection ameliorates experimental autoimmune encephalitis","authors":"Divyasha Saxena , Kelly Walter , Elizabeth Amona , Maiying Kong , Stanley Perlman , Jian Zheng","doi":"10.1016/j.jaut.2025.103504","DOIUrl":"10.1016/j.jaut.2025.103504","url":null,"abstract":"<div><h3>Background</h3><div>Central nervous system (CNS) infections contribute to the development of neuroinflammation and neurodegenerative diseases. However, the mechanisms underlying the correlation between CNS infection and subsequent inflammatory course remain largely unknown.</div></div><div><h3>Methods</h3><div>Here, we addressed this question by infecting mice with a sublethal dose of a well-studied neurotropic coronavirus, mouse hepatitis virus (MHV), and investigated the effects of infection on the subsequent induction of a mouse multiple sclerosis (MS) model (myelin oligodendrocyte glycoprotein 35-55 (MOG<sub>35-55</sub>) peptide-induced experimental autoimmune encephalitis (EAE)).</div></div><div><h3>Results</h3><div>Unexpectedly, C57BL/6J mice that recovered from MHV infection showed alleviated clinical signs of induced EAE. Mechanistically, this protection is mediated by a novel CNS-resident Foxp3<sup>+</sup> CD8 T cell population induced by interleukin (IL)-10, which was secreted by myeloid cells that infiltrated the MHV-infected CNS as part of the MHV-specific immune response. These Foxp3<sup>+</sup> CD8 T cells ameliorated EAE severity by decreasing the quantity and function of autoreactive CD4 and CD8 T cell infiltrating CNS independent of antigen specificity, as well as by inhibiting the activation of microglia accumulating in the affected spinal cords (SCs). The persistence of these Foxp3<sup>+</sup> CD8 T cells in the CNS may contribute to the long-term post-acute sequelae of infection.</div></div><div><h3>Conclusion</h3><div>This study reveals a novel post-infectious anti-inflammatory milieu that develops in MHV-infected CNS of MHV and leads to the generation of Foxp3<sup>+</sup> CD8 regulatory T cells, thereby diminishing the progression of subsequent autoimmune disease.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"158 ","pages":"Article 103504"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145584424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering Sjögren's disease: New insights and perspectives extend from advanced omics approaches and immunology 破译Sjögren的疾病：新的见解和观点从先进的组学方法和免疫学延伸。

IF 7 1区医学

Journal of autoimmunity Pub Date : 2026-02-01 Epub Date: 2026-01-06 DOI: 10.1016/j.jaut.2025.103521

Hu Chen , Naoki Kaneko , Yukiko Ohyama , Masafumi Moriyama

{"title":"Deciphering Sjögren's disease: New insights and perspectives extend from advanced omics approaches and immunology","authors":"Hu Chen , Naoki Kaneko , Yukiko Ohyama , Masafumi Moriyama","doi":"10.1016/j.jaut.2025.103521","DOIUrl":"10.1016/j.jaut.2025.103521","url":null,"abstract":"<div><div>Sjögren's disease (SjD), formerly termed Sjögren's syndrome, is a chronic autoimmune exocrinopathy that has seen substantial advances in basic research over the past decade. Classical experimental approaches have revealed immune dysregulation encompassing aberrant activation of the adaptive immune system, activation of humoral autoimmunity against autoantigens, and upstream participation of innate immune mechanisms. In parallel, with the rapid development of sequencing and omics technologies, researchers are able to use these high-throughput methods to gain a more unbiased, sytem-wide view of disease processes and pathegenesis in SjD. Among them, numerous disease-associated traits have been revealed by genomics and epigenomics, while transcriptomics, proteomics, and immunogenomics have also depicted a more detailed landscape of phenotypes and cell states of immune cells, as well as the roles of key molecules such as Toll-like receptors (TLRs) in promoting autoimmune responses, yielding profound insights for the understanding of SjD. Meanwhile, these diverse data analysis methods offer the researchers impotant tools to further invertigate and understand SjD in the future. The convergence of these modalities supports data-driven disease prediction, refined patient stratification, and identification of therapeutic targets, thereby expanding translational opportunities. Collectively, integrating innovative omics with classical methodologies provides a coherent framework for capturing the pathogenesis of SjD, linking system-wide views to experimental validation, and accelerating the path from pathobiology to precision therapeutics. This review summarizes recent advances in the understanding of the pathogenesis of SjD, lymphomagenesis in SjD, patient stratification and promising targeted therapy, and also outlines future perspectives and challenges to be addressed.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"158 ","pages":"Article 103521"},"PeriodicalIF":7.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The pivotal role of Interleukin-23 in the skin-gut-joint axis 白细胞介素-23在皮肤-肠-关节轴中的关键作用。

IF 7 1区医学

Journal of autoimmunity Pub Date : 2025-12-01 Epub Date: 2025-11-19 DOI: 10.1016/j.jaut.2025.103500

Alen Zabotti , Lucia Novelli , Michele Maria Luchetti Gentiloni , Giuliana Guggino , Ana Biljan , Ennio Lubrano , Dennis McGonagle

{"title":"The pivotal role of Interleukin-23 in the skin-gut-joint axis","authors":"Alen Zabotti , Lucia Novelli , Michele Maria Luchetti Gentiloni , Giuliana Guggino , Ana Biljan , Ennio Lubrano , Dennis McGonagle","doi":"10.1016/j.jaut.2025.103500","DOIUrl":"10.1016/j.jaut.2025.103500","url":null,"abstract":"<div><div>Interleukin-23 (IL-23) plays a pivotal role in the intricate interplay between the skin, gut, and joints, contributing significantly to the pathogenesis of various inflammatory diseases including psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD) and Behcet's disease. In recent years, several IL-23 inhibitors have been granted approval for the treatment of psoriasis, PsA and IBD. As up to one-third of patients diagnosed with psoriasis may go on to develop PsA and given the strong immunogenetic pathway incrimination of the IL-23 pathway in both psoriasis and PsA, dermatological lead therapy for psoriasis may therefore delay the development of PsA. Furthermore, patients with psoriasis or PsA are associated with increased risk of developing IBD. There is also evidence for psoriasis-directed therapy preventing IBD in keeping with the known pivotal role of IL-23 in both intestinal homeostasis and in the pathogenesis of IBD, including ulcerative colitis and Crohn's disease. This review discusses the multifaceted roles of IL-23 in regulating immune response and maintaining tissue homeostasis within the skin-gut-joint axis. In particular, the use of IL-23 inhibitors in trials in patients with psoriasis, IBD and PsA patients will also be discussed in relation to reverse translational immunology insights around inflammation in these domains.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"157 ","pages":"Article 103500"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment outcomes stratified by interferon profile and autoantibodies in rheumatoid arthritis 干扰素谱和自身抗体对类风湿关节炎的治疗效果分层。

IF 7 1区医学

Journal of autoimmunity Pub Date : 2025-12-01 Epub Date: 2025-09-30 DOI: 10.1016/j.jaut.2025.103490

Shoichi Fukui , Tohru Michitsuji , Yushiro Endo , Ayako Nishino , Kaori Furukawa , Toshimasa Shimizu , Masataka Umeda , Remi Sumiyoshi , Tomohiro Koga , Naoki Iwamoto , Mami Tamai , Tomoki Origuchi , K.A. van Schie , Yukitaka Ueki , Nobutaka Eiraku , Tamami Yoshitama , Naoki Matsuoka , Takahisa Suzuki , Akitomo Okada , Hiroaki Hamada , Shin-ya Kawashiri

{"title":"Treatment outcomes stratified by interferon profile and autoantibodies in rheumatoid arthritis","authors":"Shoichi Fukui , Tohru Michitsuji , Yushiro Endo , Ayako Nishino , Kaori Furukawa , Toshimasa Shimizu , Masataka Umeda , Remi Sumiyoshi , Tomohiro Koga , Naoki Iwamoto , Mami Tamai , Tomoki Origuchi , K.A. van Schie , Yukitaka Ueki , Nobutaka Eiraku , Tamami Yoshitama , Naoki Matsuoka , Takahisa Suzuki , Akitomo Okada , Hiroaki Hamada , Shin-ya Kawashiri","doi":"10.1016/j.jaut.2025.103490","DOIUrl":"10.1016/j.jaut.2025.103490","url":null,"abstract":"<div><div>Despite treatment advances, some rheumatoid arthritis (RA) patients fail to achieve remission with biological/targeted synthetic DMARDs. We prospectively evaluated 200 patients to determine if interferon profiles and autoantibodies predict treatment outcomes. A significant positive correlation between rheumatoid factor and IFN-γ levels was observed. Patients with high IFN-γ/low IFN-α2 profiles achieved significantly higher remission rates and demonstrated elevated B cell-stimulating cytokines with distinct immunological clustering patterns. This group showed superior responses to IL-6 inhibitors. Anti-carbamylated protein IgM antibodies differed significantly between groups. Interferon profiling offers a practical screening approach for personalized therapy selection in RA.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"157 ","pages":"Article 103490"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternate splicing converts human CD137 from costimulatory to immunosuppressive function 交替剪接将人CD137从共刺激功能转化为免疫抑制功能

IF 7 1区医学

Journal of autoimmunity Pub Date : 2025-12-01 Epub Date: 2025-11-07 DOI: 10.1016/j.jaut.2025.103498

Manuel Rojas , Luke S. Heuer , Weici Zhang , Nicolle Sweeney , Carolina Ramírez-Santana , Patrick S.C. Leung , Alvin Lam , Shraddha Kamat , Andrew R. Mendelsohn , Manley Huang , Bo Yu , Paulina Ackerman , Qisheng Wei , James W. Larrick , Yi-Guang Chen , William M. Ridgway

{"title":"Alternate splicing converts human CD137 from costimulatory to immunosuppressive function","authors":"Manuel Rojas , Luke S. Heuer , Weici Zhang , Nicolle Sweeney , Carolina Ramírez-Santana , Patrick S.C. Leung , Alvin Lam , Shraddha Kamat , Andrew R. Mendelsohn , Manley Huang , Bo Yu , Paulina Ackerman , Qisheng Wei , James W. Larrick , Yi-Guang Chen , William M. Ridgway","doi":"10.1016/j.jaut.2025.103498","DOIUrl":"10.1016/j.jaut.2025.103498","url":null,"abstract":"<div><div>Human membrane-bound CD137 (mCD137) is a well-known costimulatory molecule; however, it is alternatively spliced into two transcripts (sCD137-1, 2) whose function is not yet known. Here, we show that sCD137 isoforms lack the CRD4 region and form unique structures compared to mCD137. Human activated Tregs produce both <em>CD137</em> splice isoforms, which are rapidly upregulated after cell activation, and identify an activated Treg phenotype along with <em>FOXP3</em>, <em>CTLA4</em>, and <em>sCTLA4</em>. We engineered recombinant Fc-Hu-sCD137 variants, which are immunosuppressive, inhibiting IFN-γ secretion and proliferation in purified CD4<sup>+</sup> and CD8<sup>+</sup> T cells in an APC-independent manner. These effects are mediated by the downregulation of S6 and 4EBP1 of the mTOR complex 1 pathway. Human sCD137 variants, in contrast to the membrane-bound form, are immunosuppressive and may be a novel treatment for inflammation and autoimmunity.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"157 ","pages":"Article 103498"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145463046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study 钙保护蛋白和神经丝血清水平与强化治疗下重症肌无力治疗反应相关的初步研究

IF 7 1区医学

Journal of autoimmunity Pub Date : 2025-12-01 Epub Date: 2025-09-09 DOI: 10.1016/j.jaut.2025.103476

Frauke Stascheit , Daniel Schulze , Sophie Lehnerer , Lea Gerischer , Maike Stein , Paolo Doksani , Meret Herdick , Carla Dusemund , Philipp Mergenthaler , Paul Triller , Jan D. Lünemann , Sarah Hoffmann , Andreas Meisel

{"title":"Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study","authors":"Frauke Stascheit , Daniel Schulze , Sophie Lehnerer , Lea Gerischer , Maike Stein , Paolo Doksani , Meret Herdick , Carla Dusemund , Philipp Mergenthaler , Paul Triller , Jan D. Lünemann , Sarah Hoffmann , Andreas Meisel","doi":"10.1016/j.jaut.2025.103476","DOIUrl":"10.1016/j.jaut.2025.103476","url":null,"abstract":"<div><h3>Objective</h3><div>New therapeutic options have recently emerged for patients with highly active, acetylcholine receptor antibody–positive (AChR-Ab<sup>+</sup>) generalized myasthenia gravis (gMG), including fast-acting, endplate-protective agents such as complement C5 inhibitors (C5-I) and neonatal Fc receptor inhibitors (FcRn-I). However, objective biomarkers beyond clinical scoring systems are lacking to guide individualized treatment decisions.</div></div><div><h3>Methods</h3><div>In this exploratory, prospective <em>real-world</em> study, we assessed serum calprotectin (sCLP) and serum neurofilament light chain (sNfL) levels in a total of 22 AChR-Ab<sup>+</sup> gMG patients, who were treatment-naïve for either C5-I or FcRn-I. Changes in biomarker levels were correlated with clinical response, as measured by the Myasthenia Gravis–Activities of Daily Living (MG-ADL) score.</div></div><div><h3>Results</h3><div>We observed a correlation of changes in sCLP and sNfl with clinical treatment response to C5-I and FcRn-I therapies. Specifically, rising levels of sNfL and sCLP were associated with a poor treatment response, as measured by the MG-ADL score.</div></div><div><h3>Conclusion</h3><div>Our preliminary findings suggest that markers of systemic inflammation (such as sCLP) and local destruction of the neuromuscular junction (such as sNfL) may assist in treatment decision-making for gMG patients. Larger, multicenter studies are warranted to validate these results and define their clinical utility.</div></div>","PeriodicalId":15245,"journal":{"name":"Journal of autoimmunity","volume":"157 ","pages":"Article 103476"},"PeriodicalIF":7.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0